Table 2.
Medication prescribed to participants with type 2 diabetes at the time of diagnosis and at the time of survey.
| At the Time of Diagnosis | n = 126 | (%) | At the Time of Survey | n = 126 | (%) |
|---|---|---|---|---|---|
| Metformin | 96 | (76.2) | Metformin | 71 | (56.3) |
| Sulphonylurea | 24 | (19.0) | SU | 33 | (26.2) |
| DPP-4i | 3 | (2.4) | DPP-4i | 42 | (33.3) |
| GLP-1 | 0 | (0.0) | GLP-1 RA | 11 | (8.7) |
| Insulin | 5 | (4.0) | Insulin | 31 | (24.6) |
| Other | 12 | (9.5) | Other | 2 | (1.6) |
| Complete Therapy Structure | Complete Therapy Structure | ||||
| MET | 77 | (61.1) | MET | 22 | (17.4) |
| MET + SU | 13 | (10.3) | MET + SU | 7 | (5.6) |
| SU | 5 | (3.9) | SU | 2 | (1.5) |
| MET + TZD | 1 | (0.7) | MET + DPP-4i | 20 | (15.9) |
| SU + MET + DPP-4i | 3 | (2.3) | SU + MET + DPP-4i | 14 | (11.1) |
| Insulin | 3 | (2.3) | Insulin | 29 | (23.0) |
| AGI | 1 | (0.7) | SU + DPP-4i | 4 | (3.1) |
| MET + SU + insulin | 2 | (1.5) | DPP-4i | 3 | (2.3) |
| Repaglinide | 2 | (1.5) | OAD + GLP-1 RA | 9 | (6.8) |
| Not specified OAD | 3 | (2.3) | Not specified OAD | 2 | (1.5) |
| SU + MET + TZD | 1 | (0.7) | GLP-1 RA + insulin | 2 | (1.5) |
MET, metformin; SU, sulphonylurea; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitors; DPP-4i, dipeptidyl peptidase-4 inhibitors; GLP-1 RA, glucagon-like peptide receptor agonist.